0000950170-24-018896.txt : 20240222 0000950170-24-018896.hdr.sgml : 20240222 20240222170216 ACCESSION NUMBER: 0000950170-24-018896 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240220 FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sullivan Keith J CENTRAL INDEX KEY: 0001417973 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38546 FILM NUMBER: 24665886 MAIL ADDRESS: STREET 1: C/O RELIANT TECHNOLOGIES, INC. STREET 2: 464 ELLIS STREET CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neuronetics, Inc. CENTRAL INDEX KEY: 0001227636 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3222 PHOENIXVILLE PIKE CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 877-600-7555 MAIL ADDRESS: STREET 1: 3222 PHOENIXVILLE PIKE CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: NEURONETICS INC DATE OF NAME CHANGE: 20030416 4 1 ownership.xml 4 X0508 4 2024-02-20 0001227636 Neuronetics, Inc. STIM 0001417973 Sullivan Keith J C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355 true true false false President and CEO false Common Stock 2024-02-20 4 S false 23958 2.96 D 1434171 D The sales reported in this Form 4 were non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a restricted stock unit award. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $2.84 to $3.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ W. Andrew Macan, as Attorney-in-Fact 2024-02-22